1
|
Ferguson M, Murray A, Pliamm L, Rombo L, Sanmartin Berglund J, David MP, De Schrevel N, Maschino F, Kotb S, Olivier A, Hulstrøm V. Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults. Vaccine X 2024; 18:100494. [PMID: 38746060 PMCID: PMC11090873 DOI: 10.1016/j.jvacx.2024.100494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Revised: 04/23/2024] [Accepted: 04/26/2024] [Indexed: 05/16/2024] Open
Abstract
Background Previous phase 3 studies showed that the AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine for older adults (RSVPreF3 OA) is well tolerated and efficacious in preventing RSV-associated lower respiratory tract disease in adults ≥ 60 years of age. This study evaluated lot-to-lot immunogenicity consistency, reactogenicity, and safety of three RSVPreF3 OA lots. Methods This phase 3, multicenter, double-blind study randomized (1:1:1) participants ≥ 60 years of age to receive one of three RSVPreF3 OA lots. Serum RSVPreF3-binding immunoglobulin G (IgG) concentration was assessed at baseline and 30 days post-vaccination. Lot-to-lot consistency was demonstrated if the two-sided 95 % confidence intervals (CIs) of the RSVPreF3-binding IgG geometric mean concentration (GMC) ratios between each lot pair at 30 days post-vaccination were within 0.67 and 1.50. Solicited adverse events (AEs) within four days, unsolicited AEs within 30 days, and serious AEs (SAEs) and potential immune-mediated diseases within six months post-vaccination were recorded. Results A total of 757 participants received RSVPreF3 OA, of whom 708 were included in the per-protocol set (234, 237, and 237 participants for each lot). Lot-to-lot consistency was demonstrated: GMC ratios were 1.06 (95 % CI: 0.94-1.21), 0.92 (0.81-1.04), and 0.87 (0.77-0.99) between the lot pairs (lot 1/2; 1/3; 2/3). For the three lots, the RSVPreF3-binding IgG concentration increased 11.84-, 11.29-, and 12.46-fold post-vaccination compared to baseline. The reporting rates of solicited and unsolicited AEs, SAEs, and potential immune-mediated diseases were balanced between lots. Twenty-one participants reported SAEs; one of these-a case of atrial fibrillation-was considered by the investigator as vaccine-related. SAEs with a fatal outcome were reported for four participants, none of which were considered by the investigator as vaccine-related. Conclusion This study demonstrated lot-to-lot immunogenicity consistency of three RSVPreF3 OA vaccine lots and indicated that the vaccine had an acceptable safety profile.ClinicalTrials.gov: NCT05059301.
Collapse
Affiliation(s)
- Murdo Ferguson
- Colchester Research Group, 68 Robie, Truro, NS B2N 1L2, Canada
| | - Alexander Murray
- PharmQuest, 806 Green Valley Rd Ste 305, Greensboro, NC 27408, United States
| | - Lew Pliamm
- Canadian Phase Onward Inc., Polyclinic Family and Specialty Medicine Facility, Polyclinic Family Health Group, 2 Champagne Dr, Toronto, ON M3J 0K2, Canada
| | - Lars Rombo
- Clinical Research Centre Sörmland, Eskilstuna SE-631 88, Sweden
- Department of Medical Biochemistry and Microbiology, Zoonosis Science Center, Uppsala University, Uppsala SE-751 05, Sweden
| | - Johan Sanmartin Berglund
- Department of Health, Blekinge Institute of Technology, Valhallavägen 1, Karlskrona SE-371 79, Sweden
- Department of Clinical Sciences, Lund University, BMC I12, Lund SE-221 84, Sweden
| | | | | | | | - Shady Kotb
- GSK, Avenue Fleming 20, Wavre 1300, Belgium
| | | | | |
Collapse
|
2
|
Leroux-Roels I, Van Ranst M, Vandermeulen C, Abeele CV, De Schrevel N, Salaun B, Verheust C, David MP, Kotb S, Hulstrøm V. Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study. J Infect Dis 2024; 229:355-366. [PMID: 37699064 PMCID: PMC10873183 DOI: 10.1093/infdis/jiad321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Indexed: 09/14/2023] Open
Abstract
BACKGROUND In the previous (parent) study, 2 doses of different formulations of an investigational vaccine against respiratory syncytial virus (RSVPreF3 OA) were well tolerated and immunogenic in older adults. This multicenter phase 2b extension study assessed safety and immunogenicity of a revaccination (third) dose of the 120 μg RSVPreF3-AS01E formulation. METHODS In total, 122 older adults (60-80 years), previously vaccinated with 2 doses of RSVPreF3-AS01E formulations (containing 30, 60, or 120 μg RSVPreF3 antigen), received an additional 120 μg RSVPreF3-AS01E dose 18 months after dose 2. Vaccine safety was evaluated in all participants up to 6 months and immunogenicity in participants who received 120 μg RSVPreF3-AS01E doses until 1 month after dose 3. RESULTS Similar to the parent study, mostly mild-to-moderate solicited adverse events and no vaccine-related serious adverse events or potential immune-mediated disorders were reported. Neutralizing titers and cell-mediated immune responses persisted for 18 months after 2-dose vaccination. Dose 3 increased RSV-specific neutralizing titers against RSV-A and RSV-B and median CD4+ T-cell frequencies. After dose 3, RSV-specific neutralizing titers but not CD4+ T-cell frequencies were below levels detected 1 month after dose 1. CONCLUSIONS Revaccination with 120 μg RSVPreF3-AS01E 18 months after dose 2 is well tolerated and immunogenic in older adults. CLINICAL TRIALS REGISTRATION NCT04657198; EudraCT, 2020-000692-21.
Collapse
Affiliation(s)
- Isabel Leroux-Roels
- Centre for Vaccinology, Ghent University and Ghent University HospitalGhent, Belgium
| | - Marc Van Ranst
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
| | - Corinne Vandermeulen
- Leuven University Vaccinology Centre, Katholieke Universiteit Leuven, Leuven, Belgium
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Kotb S, Haranaka M, Folschweiller N, Nakanwagi P, Verheust C, De Schrevel N, David MP, Mesaros N, Hulstrøm V. Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial. Respir Investig 2023; 61:261-269. [PMID: 36641341 DOI: 10.1016/j.resinv.2022.11.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Revised: 10/05/2022] [Accepted: 11/08/2022] [Indexed: 01/13/2023]
Abstract
BACKGROUND Respiratory syncytial virus (RSV) causes lower respiratory tract infection, with a high burden of disease among adults ≥60 years. This study assessed the safety, reactogenicity, and immunogenicity of an investigational adjuvanted RSV vaccine (RSVPreF3/AS01B) in Japanese adults aged 60-80 years. METHODS Forty participants were randomized to receive two doses of RSVPreF3/AS01B or the placebo, in a 1:1 ratio, two months apart, in this placebo-controlled study. Solicited administration-site and systemic adverse events (AEs) were collected within 7 days and unsolicited AEs within 30 days post-vaccination. Serious AEs (SAEs) and potential immune-mediated diseases (pIMDs) were collected throughout the study (12 months post-dose 2). RSVPreF3-specific immunoglobulin G (IgG) antibody concentrations and neutralizing antibody (nAb) titers against RSV-A were evaluated on day (D)1, D31, D61, D91 and those against RSV-B on D1, D31, D91. RESULTS Solicited AEs were reported more frequently in RSVPreF3/AS01B recipients (80.0%-90.0%) than in placebo recipients (10.0%-20.0%). Two RSVPreF3/AS01B recipients experienced grade 3 solicited AEs. Rate of unsolicited AEs were similar (30.0%-35.0%) in both groups. No RSVPreF3/AS01B recipient reported SAEs/pIMDs, while one placebo recipient reported two SAEs that were unrelated to vaccination. Baseline RSVPreF3-specific IgG and RSV-A/-B nAb levels were above the assay cut-off values. In the RSVPreF3/AS01B group, RSVPreF3-specific IgG concentrations increased 12.8-fold on D31 and 9.2-fold on D91 versus baseline while nAb titers increased 7.3-fold (RSV-A) and 8.4-fold (RSV-B) on D31 and 6.3-fold (RSV-A) and 9.9-fold (RSV-B) on D91. CONCLUSIONS The RSVPreF3/AS01B vaccine was well tolerated and immunogenic in older Japanese adults. CLINICAL TRIAL REGISTRATION NUMBER NCT04090658.
Collapse
Affiliation(s)
- Shady Kotb
- GSK, Avenue Flemming 20, 1300 Wavre, Belgium.
| | - Miwa Haranaka
- SOUSEIKAI PS Clinic, Random Square 8th Fl, 6-18, Tenyamachi, Hakata-Ku, Fukuoka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Kotb S, Mostafa A. Scheduled management of primary nocturnal enuresis in pediatric age group. A new approach. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00731-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Kunjachan S, Kotb S, Pola R, Pechar M, Kumar R, Singh B, Gremse F, Taleeli R, Trichard F, Motto-Ros V, Sancey L, Detappe A, Yasmin-Karim S, Protti A, Shanmugam I, Ireland T, Etrych T, Sridhar S, Tillement O, Makrigiorgos M, Berbeco RI. Author Correction: Selective Priming of Tumor Blood Vessels by Radiation Therapy Enhances Nanodrug Delivery. Sci Rep 2020; 10:15344. [PMID: 32929171 PMCID: PMC7490694 DOI: 10.1038/s41598-020-72253-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Affiliation(s)
- Sijumon Kunjachan
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.
| | - Shady Kotb
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.,Institut Lumière Matière, UMR 5306, Université Claude Bernard Lyon 1, CNRS, Villeurbanne, France
| | - Robert Pola
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovsky Square 2, 16206, Prague 6, Czech Republic
| | - Michal Pechar
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovsky Square 2, 16206, Prague 6, Czech Republic
| | - Rajiv Kumar
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.,Nanomedicine Science and Technology Center and Department of Physics, Northeastern University, Boston, MA, United States
| | - Bijay Singh
- Nanomedicine Science and Technology Center and Department of Physics, Northeastern University, Boston, MA, United States
| | - Felix Gremse
- Experimental Molecular Imaging, University Hospital and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany
| | - Reza Taleeli
- Division of Medical Physics & Engineering, University of Texas Southwestern Medical Center, Texas, United States
| | - Florian Trichard
- Institut Lumière Matière, UMR 5306, Université Claude Bernard Lyon 1, CNRS, Villeurbanne, France
| | - Vincent Motto-Ros
- Institut Lumière Matière, UMR 5306, Université Claude Bernard Lyon 1, CNRS, Villeurbanne, France
| | - Lucie Sancey
- Institute for Advanced Biosciences, UGA/INSERM U1209/CNRS UMR 5309 Joint Research Center, Grenoble, France
| | - Alexandre Detappe
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States
| | - Sayeda Yasmin-Karim
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States
| | - Andrea Protti
- Lurie Family Imaging Center, Department of Radiology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States
| | - Ilanchezhian Shanmugam
- Nanomedicine Science and Technology Center and Department of Physics, Northeastern University, Boston, MA, United States
| | - Thomas Ireland
- LA-ICP-MS and ICP-ES Laboratories, Department of Earth and Environmental Sciences, Boston University, Boston, MA, United States
| | - Tomas Etrych
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovsky Square 2, 16206, Prague 6, Czech Republic
| | - Srinivas Sridhar
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.,Nanomedicine Science and Technology Center and Department of Physics, Northeastern University, Boston, MA, United States
| | - Olivier Tillement
- Institut Lumière Matière, UMR 5306, Université Claude Bernard Lyon 1, CNRS, Villeurbanne, France
| | - Mike Makrigiorgos
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States
| | - Ross I Berbeco
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States
| |
Collapse
|
6
|
Cox S, Rousseau-Tsangaris M, Abou-Zeid N, Dalle S, Leurent P, Cutivet A, Le HH, Kotb S, Bogaert B, Gardette R, Baran Y, Holder JM, Lerner L, Blay JY, Cambrosio A, Tredan O, Denèfle P. La médecine de précision en oncologie : challenges, enjeux et nouveaux paradigmes. Bull Cancer 2019; 106:97-104. [DOI: 10.1016/j.bulcan.2019.01.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Revised: 01/08/2019] [Accepted: 01/08/2019] [Indexed: 10/27/2022]
|
7
|
Aktar R, Dietrich A, Tillner F, Kotb S, Löck S, Willers H, Baumann M, Krause M, Bütof R. Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios. Br J Radiol 2018; 92:20180539. [PMID: 30215546 DOI: 10.1259/bjr.20180539] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVE: Clinically relevant animal models of non-small cell lung carcinoma (NSCLC) are required for the validation of novel treatments. We compared two different orthotopic transplantation techniques as well as imaging modalities to identify suitable mouse models mimicking clinical scenarios. METHODS: We used three genomically diverse NSCLC cell lines [National Cancer Institute (NCI)-H1703 adenosquamous cell carcinoma, NCI-H23 adenocarcinoma and A549 adenocarcinoma) for implanting tumour cells either as spheroids or cell suspension into lung parenchyma. Bioluminescence imaging (BLI) and contrast-enhanced cone beam CT (CBCT) were performed twice weekly to monitor tumour growth. Tumour histological data and microenvironmental parameters were determined. RESULTS: Tumour development after spheroid-based transplantation differs probably due to the integrity of spheroids, as H1703 developed single localised nodules, whereas H23 showed diffuse metastatic spread starting early after transplantation. A549 transplantation as cell suspension with the help of a stereotactic system was associated with initial single localised tumour growth and eventual metastatic spread. Imaging techniques were successfully applied to monitor longitudinal tumour growth: BLI revealed highly sensitive qualitative data, whereas CBCT was associated with less sensitive quantitative data. Histology revealed significant model-dependent heterogeneity in proliferation, hypoxia, perfusion and necrosis. CONCLUSION: Our developed orthotopic NSCLC tumours have similarity with biological growth behaviour comparable to that seen in the clinic and could therefore be used as attractive models to study tumour biology and evaluate new therapeutic strategies. The use of human cancer cell lines facilitates testing of different genomic tumour profiles that may affect treatment outcomes. ADVANCES IN KNOWLEDGE: The combination of different imaging modalities to identify tumour growth with subsequent use in treatment planning and orthotopic transplantation techniques to develop initially single lesions to ultimate metastases pave the way towards representative pre-clinical NSCLC models for experimental testing of novel therapeutic options in future studies.
Collapse
Affiliation(s)
- Rozina Aktar
- 1 OncoRay ̶ National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf , Dresden , Germany.,2 German Cancer Consortium (DKTK), Partner Site Dresden , Dresden , Germany.,3 German Cancer Research Center (DKFZ) , Heidelberg , Germany
| | - Antje Dietrich
- 1 OncoRay ̶ National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf , Dresden , Germany.,2 German Cancer Consortium (DKTK), Partner Site Dresden , Dresden , Germany.,3 German Cancer Research Center (DKFZ) , Heidelberg , Germany
| | - Falk Tillner
- 1 OncoRay ̶ National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf , Dresden , Germany.,4 Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden , Dresden , Germany.,5 Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology ̶ OncoRay , Dresden , Germany
| | - Shady Kotb
- 1 OncoRay ̶ National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf , Dresden , Germany.,2 German Cancer Consortium (DKTK), Partner Site Dresden , Dresden , Germany.,3 German Cancer Research Center (DKFZ) , Heidelberg , Germany
| | - Steffen Löck
- 1 OncoRay ̶ National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf , Dresden , Germany.,2 German Cancer Consortium (DKTK), Partner Site Dresden , Dresden , Germany.,3 German Cancer Research Center (DKFZ) , Heidelberg , Germany.,4 Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden , Dresden , Germany
| | - Henning Willers
- 6 Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School , Boston, MA , USA
| | - Michael Baumann
- 1 OncoRay ̶ National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf , Dresden , Germany.,2 German Cancer Consortium (DKTK), Partner Site Dresden , Dresden , Germany.,3 German Cancer Research Center (DKFZ) , Heidelberg , Germany.,4 Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden , Dresden , Germany.,5 Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology ̶ OncoRay , Dresden , Germany
| | - Mechthild Krause
- 1 OncoRay ̶ National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf , Dresden , Germany.,2 German Cancer Consortium (DKTK), Partner Site Dresden , Dresden , Germany.,3 German Cancer Research Center (DKFZ) , Heidelberg , Germany.,4 Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden , Dresden , Germany.,5 Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology ̶ OncoRay , Dresden , Germany.,7 National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and; Helmholtz Association/Helmholtz-Zentrum Dresden-Rossendorf (HZDR) , Dresden , Germany
| | - Rebecca Bütof
- 1 OncoRay ̶ National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf , Dresden , Germany.,3 German Cancer Research Center (DKFZ) , Heidelberg , Germany.,4 Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden , Dresden , Germany.,7 National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and; Helmholtz Association/Helmholtz-Zentrum Dresden-Rossendorf (HZDR) , Dresden , Germany
| |
Collapse
|
8
|
Ibrahim H, Kotb S, Elfayoumy H, Abd Allah A, Kasem A, Salem A, Abd Elhamid M, Mursi K, Abd Elrazzak O. Enhanced recovery protocol versus standard protocol for radical cystectomy: Results of a prospective randomized study. European Urology Supplements 2018; 17:e1023. [DOI: 10.1016/s1569-9056(18)31543-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
|
9
|
Kotb S, lux F, Claire-Rodriguez-Lafrasse, Tillement O, Sancey L. Nanoparticle Enhanced MRI-Guided Radiation Therapy: Final proof of concept before phase I trial. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)30125-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Kotb S, Detappe A, Lux F, Appaix F, Barbier EL, Tran VL, Plissonneau M, Gehan H, Lefranc F, Rodriguez-Lafrasse C, Verry C, Berbeco R, Tillement O, Sancey L. Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial. Theranostics 2016; 6:418-27. [PMID: 26909115 PMCID: PMC4737727 DOI: 10.7150/thno.14018] [Citation(s) in RCA: 102] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2015] [Accepted: 12/12/2015] [Indexed: 12/23/2022] Open
Abstract
Nanoparticles containing high-Z elements are known to boost the efficacy of radiation therapy. Gadolinium (Gd) is particularly attractive because this element is also a positive contrast agent for MRI, which allows for the simultaneous use of imaging to guide the irradiation and to delineate the tumor. In this study, we used the Gd-based nanoparticles, AGuIX®. After intravenous injection into animals bearing B16F10 tumors, some nanoparticles remained inside the tumor cells for more than 24 hours, indicating that a single administration of nanoparticles might be sufficient for several irradiations. Combining AGuIX® with radiation therapy increases tumor cell death, and improves the life spans of animals bearing multiple brain melanoma metastases. These results provide preclinical proof-of-concept for a phase I clinical trial.
Collapse
|
11
|
Moussaron A, Vibhute S, Bianchi A, Gündüz S, Kotb S, Sancey L, Motto-Ros V, Rizzitelli S, Crémillieux Y, Lux F, Logothetis NK, Tillement O, Angelovski G. Ultrasmall Nanoplatforms as Calcium-Responsive Contrast Agents for Magnetic Resonance Imaging. Small 2015; 11:4900-4909. [PMID: 26179212 DOI: 10.1002/smll.201500312] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/01/2015] [Revised: 06/17/2015] [Indexed: 06/04/2023]
Abstract
The preparation of ultrasmall and rigid platforms (USRPs) that are covalently coupled to macrocycle-based, calcium-responsive/smart contrast agents (SCAs), and the initial in vitro and in vivo validation of the resulting nanosized probes (SCA-USRPs) by means of magnetic resonance imaging (MRI) is reported. The synthetic procedure is robust, allowing preparation of the SCA-USRPs on a multigram scale. The resulting platforms display the desired MRI activity—i.e., longitudinal relaxivity increases almost twice at 7 T magnetic field strength upon saturation with Ca(2+). Cell viability is probed with the MTT assay using HEK-293 cells, which show good tolerance for lower contrast agent concentrations over longer periods of time. On intravenous administration of SCA-USRPs in living mice, MRI studies indicate their rapid accumulation in the renal pelvis and parenchyma. Importantly, the MRI signal increases in both kidney compartments when CaCl2 is also administrated. Laser-induced breakdown spectroscopy experiments confirm accumulation of SCA-USRPs in the renal cortex. To the best of our knowledge, these are the first studies which demonstrate calcium-sensitive MRI signal changes in vivo. Continuing contrast agent and MRI protocol optimizations should lead to wider application of these responsive probes and development of superior functional methods for monitoring calcium-dependent physiological and pathological processes in a dynamic manner.
Collapse
Affiliation(s)
- Albert Moussaron
- Laboratoire MATEIS, INSA de Lyon, 69621, Villeurbanne Cedex, France
| | - Sandip Vibhute
- Department for Physiology of Cognitive Processes, Max Planck Institute for Biological Cybernetics, 72076, Tübingen, Germany
| | - Andrea Bianchi
- CRMSB, UMR 5536, Université Bordeaux, 33076, Bordeaux, France
| | - Serhat Gündüz
- MR Neuroimaging Agents Group, Max Planck Institute for Biological Cybernetics, Spemannstr. 41, 72076, Tübingen, Germany
| | - Shady Kotb
- Institut Lumière Matière, UMR CNRS 5306 - Université Lyon 1, 69622, Villeurbanne Cedex, France
| | - Lucie Sancey
- Institut Lumière Matière, UMR CNRS 5306 - Université Lyon 1, 69622, Villeurbanne Cedex, France
| | - Vincent Motto-Ros
- Institut Lumière Matière, UMR CNRS 5306 - Université Lyon 1, 69622, Villeurbanne Cedex, France
| | | | | | - Francois Lux
- Institut Lumière Matière, UMR CNRS 5306 - Université Lyon 1, 69622, Villeurbanne Cedex, France
| | - Nikos K Logothetis
- Department for Physiology of Cognitive Processes, Max Planck Institute for Biological Cybernetics, 72076, Tübingen, Germany
- Department of Imaging Science and Biomedical Engineering, University of Manchester, Manchester, M13 9PT, UK
| | - Olivier Tillement
- Institut Lumière Matière, UMR CNRS 5306 - Université Lyon 1, 69622, Villeurbanne Cedex, France
| | - Goran Angelovski
- MR Neuroimaging Agents Group, Max Planck Institute for Biological Cybernetics, Spemannstr. 41, 72076, Tübingen, Germany
| |
Collapse
|
12
|
Sancey L, Kotb S, Truillet C, Appaix F, Marais A, Thomas E, van der Sanden B, Klein JP, Laurent B, Cottier M, Antoine R, Dugourd P, Panczer G, Lux F, Perriat P, Motto-Ros V, Tillement O. Long-term in vivo clearance of gadolinium-based AGuIX nanoparticles and their biocompatibility after systemic injection. ACS Nano 2015; 9:2477-88. [PMID: 25703068 DOI: 10.1021/acsnano.5b00552] [Citation(s) in RCA: 83] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
We previously reported the synthesis of gadolinium-based nanoparticles (NPs) denoted AGuIX (activation and guiding of irradiation by X-ray) NPs and demonstrated their potential as an MRI contrast agent and their efficacy as radiosensitizing particles during X-ray cancer treatment. Here we focus on the elimination kinetics of AGuIX NPs from the subcellular to whole-organ scale using original and complementary methods such as laser-induced breakdown spectroscopy (LIBS), intravital two-photon microscopy, inductively coupled plasma optical emission spectrometry (ICP-OES), transmission electron microscopy (TEM), and electrospray ionization mass spectrometry (ESI-MS). This combination of techniques allows the exact mechanism of AGuIX NPs elimination to be elucidated, including their retention in proximal tubules and their excretion as degraded or native NPs. Finally, we demonstrated that systemic AGuIX NP administration induced moderate and transient effects on renal function. These results provide useful and promising preclinical information concerning the safety of theranostic AGuIX NPs.
Collapse
Affiliation(s)
- Lucie Sancey
- †Institut lumière matière, UMR5306, Université Claude Bernard Lyon1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| | - Shady Kotb
- †Institut lumière matière, UMR5306, Université Claude Bernard Lyon1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| | - Charles Truillet
- †Institut lumière matière, UMR5306, Université Claude Bernard Lyon1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| | | | - Arthur Marais
- †Institut lumière matière, UMR5306, Université Claude Bernard Lyon1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| | - Eloïse Thomas
- †Institut lumière matière, UMR5306, Université Claude Bernard Lyon1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| | | | - Jean-Philippe Klein
- §LINA EA 4624-Laboratoire Interdisciplinaire d'étude des Nanoparticules Aérosolisées, Saint Etienne, 42023, France
| | - Blandine Laurent
- §LINA EA 4624-Laboratoire Interdisciplinaire d'étude des Nanoparticules Aérosolisées, Saint Etienne, 42023, France
| | - Michèle Cottier
- §LINA EA 4624-Laboratoire Interdisciplinaire d'étude des Nanoparticules Aérosolisées, Saint Etienne, 42023, France
| | - Rodolphe Antoine
- †Institut lumière matière, UMR5306, Université Claude Bernard Lyon1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| | - Philippe Dugourd
- †Institut lumière matière, UMR5306, Université Claude Bernard Lyon1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| | - Gérard Panczer
- †Institut lumière matière, UMR5306, Université Claude Bernard Lyon1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| | - François Lux
- †Institut lumière matière, UMR5306, Université Claude Bernard Lyon1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| | - Pascal Perriat
- ∥MATEIS, UMR 5510 INSA Lyon-CNRS, INSA Lyon, 69621 Villeurbanne, France
| | - Vincent Motto-Ros
- †Institut lumière matière, UMR5306, Université Claude Bernard Lyon1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| | - Olivier Tillement
- †Institut lumière matière, UMR5306, Université Claude Bernard Lyon1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| |
Collapse
|
13
|
Sancey L, Motto-Ros V, Busser B, Kotb S, Benoit JM, Piednoir A, Lux F, Tillement O, Panczer G, Yu J. Laser spectrometry for multi-elemental imaging of biological tissues. Sci Rep 2014; 4:6065. [PMID: 25338518 PMCID: PMC4206947 DOI: 10.1038/srep06065] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2014] [Accepted: 07/25/2014] [Indexed: 11/26/2022] Open
Abstract
An increasing interest has arisen in research focused on metallic and organic ions that play crucial roles in both physiological and pathological metabolic processes. Current methods for the observation of trace elements in biological tissues at microscopic spatial resolution often require equipment with high complexity. We demonstrate a novel approach with an all-optical design and multi-elemental scanning imaging, which is unique among methods of elemental detection because of its full compatibility with standard optical microscopy. This approach is based on laser-induced breakdown spectroscopy (LIBS), which allows the elements in a tissue sample to be directly detected and quantified under atmospheric pressure. We successfully applied this method to murine kidneys with 10 µm resolution and a ppm-level detection limit to analyze the renal clearance of nanoparticles. These results offer new insight into the use of laser spectrometry in biomedical applications in the field of label-free elemental mapping of biological tissues.
Collapse
Affiliation(s)
- L Sancey
- 1] Institut Lumière Matière, UMR5306 Université Lyon 1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France [2]
| | - V Motto-Ros
- 1] Institut Lumière Matière, UMR5306 Université Lyon 1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France [2]
| | - B Busser
- Université Joseph Fourier, Inserm U823, IAB, F-38000 Grenoble, France
| | - S Kotb
- Institut Lumière Matière, UMR5306 Université Lyon 1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| | - J M Benoit
- Institut Lumière Matière, UMR5306 Université Lyon 1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| | - A Piednoir
- Institut Lumière Matière, UMR5306 Université Lyon 1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| | - F Lux
- Institut Lumière Matière, UMR5306 Université Lyon 1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| | - O Tillement
- Institut Lumière Matière, UMR5306 Université Lyon 1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| | - G Panczer
- Institut Lumière Matière, UMR5306 Université Lyon 1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| | - J Yu
- Institut Lumière Matière, UMR5306 Université Lyon 1-CNRS, Université de Lyon 69622 Villeurbanne cedex, France
| |
Collapse
|
14
|
Sancey L, Lux F, Kotb S, Roux S, Dufort S, Bianchi A, Crémillieux Y, Fries P, Coll JL, Rodriguez-Lafrasse C, Janier M, Dutreix M, Barberi-Heyob M, Boschetti F, Denat F, Louis C, Porcel E, Lacombe S, Le Duc G, Deutsch E, Perfettini JL, Detappe A, Verry C, Berbeco R, Butterworth KT, McMahon SJ, Prise KM, Perriat P, Tillement O. The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy. Br J Radiol 2014; 87:20140134. [PMID: 24990037 PMCID: PMC4453146 DOI: 10.1259/bjr.20140134] [Citation(s) in RCA: 143] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
A new efficient type of gadolinium-based theranostic agent (AGuIX®) has recently been developed for MRI-guided radiotherapy (RT). These new particles consist of a polysiloxane network surrounded by a number of gadolinium chelates, usually 10. Owing to their small size (<5 nm), AGuIX typically exhibit biodistributions that are almost ideal for diagnostic and therapeutic purposes. For example, although a significant proportion of these particles accumulate in tumours, the remainder is rapidly eliminated by the renal route. In addition, in the absence of irradiation, the nanoparticles are well tolerated even at very high dose (10 times more than the dose used for mouse treatment). AGuIX particles have been proven to act as efficient radiosensitizers in a large variety of experimental in vitro scenarios, including different radioresistant cell lines, irradiation energies and radiation sources (sensitizing enhancement ratio ranging from 1.1 to 2.5). Pre-clinical studies have also demonstrated the impact of these particles on different heterotopic and orthotopic tumours, with both intratumoural or intravenous injection routes. A significant therapeutical effect has been observed in all contexts. Furthermore, MRI monitoring was proven to efficiently aid in determining a RT protocol and assessing tumour evolution following treatment. The usual theoretical models, based on energy attenuation and macroscopic dose enhancement, cannot account for all the results that have been obtained. Only theoretical models, which take into account the Auger electron cascades that occur between the different atoms constituting the particle and the related high radical concentrations in the vicinity of the particle, provide an explanation for the complex cell damage and death observed.
Collapse
Affiliation(s)
- L Sancey
- 1 Institut Lumière Matière, UMR5306 Université Lyon 1-CNRS, Team FENNEC, Université de Lyon, Villeurbanne Cedex, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Sancey L, Motto-Ros V, Kotb S, Wang X, Lux F, Panczer G, Yu J, Tillement O. Laser-induced breakdown spectroscopy: a new approach for nanoparticle's mapping and quantification in organ tissue. J Vis Exp 2014:51353. [PMID: 24962015 PMCID: PMC4195480 DOI: 10.3791/51353] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
Emission spectroscopy of laser-induced plasma was applied to elemental analysis of biological samples. Laser-induced breakdown spectroscopy (LIBS) performed on thin sections of rodent tissues: kidneys and tumor, allows the detection of inorganic elements such as (i) Na, Ca, Cu, Mg, P, and Fe, naturally present in the body and (ii) Si and Gd, detected after the injection of gadolinium-based nanoparticles. The animals were euthanized 1 to 24 hr after intravenous injection of particles. A two-dimensional scan of the sample, performed using a motorized micrometric 3D-stage, allowed the infrared laser beam exploring the surface with a lateral resolution less than 100 μm. Quantitative chemical images of Gd element inside the organ were obtained with sub-mM sensitivity. LIBS offers a simple and robust method to study the distribution of inorganic materials without any specific labeling. Moreover, the compatibility of the setup with standard optical microscopy emphasizes its potential to provide multiple images of the same biological tissue with different types of response: elemental, molecular, or cellular.
Collapse
Affiliation(s)
| | | | - Shady Kotb
- ILM-FENNEC UMR 5306, CNRS - Université Lyon 1
| | | | | | | | - Jin Yu
- ILM-PUBLI UMR 5306, CNRS - Université Lyon 1
| | | |
Collapse
|
16
|
El-Wahidi GF, Eldesoky I, Kotb S, Awad I, Thabet M, Thaleh Y. Neoadjuvant chemotherapy & low dose extracorporeal irradiation for treatment of osteosarcoma. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9074] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - S. Kotb
- Faculty of medicine, Mansoura, Egypt
| | - I. Awad
- Faculty of medicine, Mansoura, Egypt
| | - M. Thabet
- Faculty of medicine, Mansoura, Egypt
| | - Y. Thaleh
- Faculty of medicine, Mansoura, Egypt
| |
Collapse
|
17
|
Abstract
This study discusses our initial experience in the field of laparoscopic management of bladder carcinoma. Ten patients with invasive bladder tumors of variable histology and ranging from stage T2 to T3b were submitted to this procedure. Intraoperative assessment, lateral dissection, posterior dissection, anterior dissection, and urethral transection were achieved laparoscopically. The specimen retrieval and continent pouch construction was performed through a limited abdominal incision. This new regimen allows precise radical lymphadenectomy, early postoperative mobility, fewer wound complications, and shorter hospital stay. The early postoperative results of this procedure are encouraging. Modification and continuous refinement of the technique is still ongoing.
Collapse
Affiliation(s)
- A Denewer
- Mansoura Surgical Oncology Unit, Faculty of Medicine, Mansoura University, Ghomhoria Street, PO Box 35516-37, Mansoura, Egypt
| | | | | | | |
Collapse
|
18
|
Effat L, Kuzmin A, Kasem N, Meguid NA, Kotb S, Eisensmith RC, Temtamy SA, Rushdi S, Woo S, el-Awady M. Haplotypes and mutations of the PAH locus in Egyptian families with PKU. Eur J Hum Genet 1999; 7:259-62. [PMID: 10196714 DOI: 10.1038/sj.ejhg.5200270] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
A high degree of molecular heterogeneneity at the phenylalanine hydroxylase (PAH) locus was established by examining RFLP haplotypes and PAH mutations in the families of 13 Egyptians with phenylketenouria (PKU). Thirteen different haplotypes were unequivocally determined in these kindreds. Haplotypes 1.8, 3.9, 4.3, 7.8, 22.11, 27.6, and 52.8 were found segregating with normal chromosomes, whilst haplotypes 1.8, 5.9, 23.8, 32.8, the newly assigned 73.9, and two as yet incomplete but novel haplotypes were found segregating with the mutant chromosomes. There was no particular preference for a single haplotype among normal or mutant chromosomes. Nine different mutations were also identified among the 26 alleles. IVS 10nt11g (8/26), IVS 2nt5g-c (4/26), R261Q (3/26), R176X (2/26), Y206D (2/26), S231P (2/26), Y198fs [593-614del22bp]; (2/26), G46fs [136/137delG]; (1/26), and E178G (1/26). Six of these mutations (IVS 2nt5g-c, R176X, Y198fs, R261Q, S231P, and IVS 10nt11g) are common to other Mediterranean populations. Two mutations not previously reported in the Mediterranean basin were also observed (Y206D and G46fs). These intriguing preliminary findings confirm IVS 10nt11g as a major mutation among Mediterranean mutations and demonstrate the need for a more comprehensive study of Arab populations to confirm the uniqueness of the two novel mutations to the Egyptian population.
Collapse
Affiliation(s)
- L Effat
- Department of Human Genetics, National Research Center, Egypt.
| | | | | | | | | | | | | | | | | | | |
Collapse
|